Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

520
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
520
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

340
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
340
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

74.5K
Overview
74.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Carmustine-, Lomustine-, and Nitrosourea-Free Conditioning Regimens for Autologous HCT (Auto-HCT) in Lymphoma: Results From the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR).

Transplantation and cellular therapy·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Haploidentical Versus HLA-matched Unrelated Donors for Hematopoietic Cell Transplantation in Acute Leukemia: A Multicenter Observational Study in a Developing Country Facilitated by Collaboration Between the CIBMTR and the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO).

Transplantation and cellular therapy·2026
Same author

Unraveling the Role of Zonulin in Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study.

International journal of molecular sciences·2026
Same author

Myelodysplastic Syndromes in VEXAS.

Blood advances·2026
Same author

High-performance multicenter Echocardiographic diagnostic score for Transthyretin Cardiac amyloidosis: results from the REACT-SP multicenter retrospective Cohort study.

Heart & lung : the journal of critical care·2026

Related Experiment Video

Updated: Sep 25, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K

Immunosuppressive therapy in severe aplastic anemia.

Bhavisha A Patel1, Danielle M Townsley2, Phillip Scheinberg3

  • 1National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, MD.

Seminars in Hematology
|May 1, 2022
PubMed
Summary

Adding eltrombopag (EPAG) to immunosuppressive therapy (IST) significantly improves treatment response rates for severe aplastic anemia. While this combination enhances recovery, further research is needed to prevent relapses and reduce clonal evolution.

Keywords:
Aplastic anemiaClonal evolutionEltrombopagImmunosuppressive therapyRelapseSurvival

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.5K
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.4K

Related Experiment Videos

Last Updated: Sep 25, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.5K
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.4K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Severe aplastic anemia (SAA) is a life-threatening condition characterized by pancytopenia and hypocellular bone marrow.
  • The immune-mediated pathophysiology of SAA is increasingly understood, yet the initial trigger remains unknown.
  • Standard treatment options include immunosuppressive therapy (IST) and hematopoietic stem cell transplant.

Purpose of the Study:

  • To evaluate the efficacy of adding eltrombopag (EPAG), a thrombopoietin receptor agonist, to the standard IST regimen for severe aplastic anemia.
  • To assess the impact of EPAG on response rates, complete count recovery, and the risk of clonal evolution to myeloid malignancies.
  • To identify areas for further optimization of upfront therapy to improve long-term outcomes in SAA.

Main Methods:

  • Retrospective analysis of patients with severe aplastic anemia treated with IST.
  • Comparison of outcomes between patients receiving standard IST versus IST combined with eltrombopag (EPAG).
  • Assessment of hematologic response rates, complete count recovery, and incidence of clonal evolution.

Main Results:

  • The combination of IST and EPAG achieved significantly higher hematologic response rates (nearly 80%) compared to IST alone (60-65%).
  • Complete count recovery increased substantially to almost 40% with the addition of EPAG.
  • Importantly, the addition of EPAG to frontline IST did not increase the risk of high-grade clonal evolution to myeloid malignancies.

Conclusions:

  • Adding eltrombopag (EPAG) to immunosuppressive therapy (IST) represents a significant advancement in treating severe aplastic anemia, markedly improving response rates and complete recovery.
  • This combination therapy appears safe concerning the risk of clonal evolution in the frontline setting.
  • Despite these improvements, relapse remains a challenge, necessitating further optimization of treatment protocols for enhanced long-term patient outcomes.